Post-Operative Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Post-Operative Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.

Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 12, 34, 13, 5, 41, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Unknown stages comprise 1, 1, 3 and 1 molecules, respectively.

Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

Acadia Pharmaceuticals Inc
AcelRx Pharmaceuticals Inc
Adare Pharma Solutions
Algomedix Inc
Allay Therapeutics Inc
Altus Formulation Inc
AmacaThera Inc
Andros Pharmaceuticals Co Ltd
AngioChem Inc
Antibe Therapeutics Inc
Bayer AG
Beijing Join Chain Medicine Co Ltd
Benuvia Therapeutics Inc
Brainfarma Chemical and Pharmaceutical Industry SA
Cali Pharmaceuticals LLC
Camurus AB
Cara Therapeutics Inc
Cellix Bio Pvt Ltd
Chromocell Corp
Clexio Biosciences Ltd
Concentric Analgesics Inc
Cytogel Pharma LLC
Daewoong Pharmaceutical Co Ltd
Dompe Farmaceutici SpA
Douleur Therapeutics Inc
Eliem Therapeutics Inc
Ethismos Research Inc
Euclises Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc
Eurofarma Laboratorios SA
Flexion Therapeutics Inc
Fujimoto Pharmaceutical Corp
G2GBIO Inc
Grunenthal GmbH
Guangdong Jiabo Pharmaceutical Co Ltd
Hana Pharm Co Ltd
Hefei Cosource Pharmaceutical Inc
Heron Therapeutics Inc
Hyloris Pharmaceuticals SA
IACTA Pharmaceuticals Inc
InSitu Biologics LLC
Insys Therapeutics Inc (Inactive)
InterK Peptide Therapeutics Ltd
Ionis Pharmaceuticals Inc
iX Biopharma Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Huatai Chenguang Pharmaceutical Co Ltd
Liquidia Technologies Inc
Lumosa Therapeutics Co Ltd
Luye Pharma Group Ltd
Medical Developments International Ltd
MedinCell SA
Mundipharma International Ltd
Nang Kuang Pharmaceutical Co Ltd
Nanjing Delova Biotech Co Ltd
Nanjing Heron Pharmaceutical Science and Technology Co Ltd
Neumentum Inc
Neurocarrus Inc
NeuroPn Therapeutics LLC
Nevakar Injectables Inc
Ocular Therapeutix Inc
Pacira BioSciences Inc
PainReform Ltd
Pharmazz Inc
PhytoHealth Corp
PolyPid Ltd
Revogenex Inc
RHNanopharmacuticals LLC
Rottapharm Biotech Srl
Sedor Pharmaceuticals LLC
Seelos Therapeutics, Inc.
Serina Therapeutics Inc
Shijiazhuang Yiling Pharmaceutical Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SiteOne Therapeutics Inc
Sonoran Biosciences Inc
Sotex Pharm Firm
Stragen New Molecules
Taiwan Liposome Co Ltd
Teikoku Pharma USA Inc
Theracaine LLC
Trevena Inc
Tris Pharma Inc
Vertex Pharmaceuticals Inc
Viatris Inc
Virpax Pharmaceuticals Inc
Vivozon Inc
Xgene Pharmaceutical Inc
Xigen SA
Yichang Humanwell Pharmaceutical Co Ltd